Will AZ01 win the race as the “first” drug applying triazole click chemistry?
10/18/2011 Allozyne announces positive results from multiple ascending dose (MAD) Phase 1B trial of AZ01, the lead product candidate developed by Biociphering platform, for the treatment of relapsing-remitting multiple sclerosis (RRMS). AZ01 is a next-generation long-lasting interferon beta for the treatment of MS, the chronic inflammatory and degenerative brain disease. The MAD study suggested an improved tolerability profile in monthly therapy.
Allozyne Biociphering platforms enable site-specific incorporation of non-natural amino acid in the target protein, allowing further bioconjugation with a host of molecules for enhanced therapeutic properties of target proteins. Click chemistry has been powering this highly efficient conjugation.
Two versions of Biciphering platforms exist: CAESAR (E Coli based) and VIGENERE (mammalian cells based). The former has produced AZ01 (MS) and AZ17 (Crohn’s Disease) in the pipeline, while the latter has AZ05 (Oncology).
See a previous announcement on AZ01 by Allozyne
7/15/2010 Allozyne licenses Click Chemistry from Scripps